Lilly's drug extends lives in lung cancer trial after failing in breast study
This article was originally published in Scrip
Executive Summary
Eli Lilly said its ramucirumab extended lives of lung cancer patients in a late-stage study of the drug. Shares of the US drug maker jumped 5% on the news.